{"id":"9765d97d8413","type":"article","url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","title":"Late trombotische events na bioresorbeerbare scaffold: meta-analyse van gerandomiseerde trials","title_en":"Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehx155","source_url":"https://doi.org/10.1093/eurheartj/ehx155","authors":["Carlos Collet","Taku Asano","Yosuke Miyazaki","Erhan Tenekecioglu","Yuki Katagiri","Yohei Sotomi","Rafael Cavalcante","Robbert J de Winter","Takeshi Kimura","Runlin Gao","Serban Puricel","Stéphane Cook","Davide Capodanno","Yoshinobu Onuma","Patrick W Serruys"],"significance":7,"published":"2017-09-01","source_date":"2017-09-01","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/implanteerbare-loop-recorder/","https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"This meta-analysis quantified the risk of late thrombotic events after bioresorbable scaffold implantation, demonstrating a significantly higher rate of very late scaffold thrombosis compared with metallic everolimus-eluting stents.","created":"2026-07-03T10:26:52Z","updated":"2026-07-03T13:26:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Meta-analyse die het risico op late trombotische events na bioresorbeerbare scaffold-implantatie kwantificeerde. Definitief bewijs voor het verhoogde langetermijnrisico.","abstract_original":"AIMS: To compare the long-term safety and efficacy of bioresorbable vascular scaffold (BVS) with everolimus-eluting stent (EES) after percutaneous coronary interventions. METHODS AND RESULTS: A systematic review and meta-analysis of randomized clinical trials comparing clinical outcomes of patients treated with BVS and EES with at least 24 months follow-up was performed. Adjusted random-effect model by the Knapp-Hartung method was used to compute odds ratios (OR) and 95% confidence intervals (CI). The primary safety outcome of interest was the risk of definite/probable device thrombosis (DT). The primary efficacy outcome of interest was the risk of target lesion failure (TLF). Five randomized clinical trials (n = 1730) were included. Patients treated with Absorb BVS had a higher risk of definite/probable DT compared with patients treated with EES (OR 2.93, 95%CI 1.37-6.26, P = 0.01). Very late DT (VLDT) occurred in 13 patients [12/996 (1.4%, 95%CI: 0.08-2.5) Absorb BVS vs. 1/701 (0.5%, 95%CI: 0.2-1.6) EES; OR 3.04; 95%CI 1.2-7.68, P = 0.03], 92% of the VLDT in the BVS group occurred in the absence of dual antiplatelet therapy (DAPT). Patients treated with Absorb BVS had a trend towards higher risk of TLF (OR 1.48, 95%CI 0.90-2.42, P = 0.09), driven by a higher risk of target vessel myocardial infarction and ischaemia-driven target lesion revascularization. No difference was found in the risk of cardiac death. CONCLUSION: Compared with EES, the use of Absorb BVS was associated with a higher rate of DT and a trend towards higher risk of TLF. VLDT occurred in 1.4% of the patients, the majority of these events occurred in the absence of DAPT."}